LARGER VIALS = LARGER SAVINGS PER mg

VIP-5

VIP-5

$62.00
$62.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

VIP-5

VIP-5

$62.00
$62.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

VIP-5 is a synthetic analogue of vasoactive intestinal peptide (VIP), a neuropeptide involved in smooth muscle relaxation, vasodilation, and immune regulation. It has been investigated for potential roles in modulating inflammation, protecting neural tissues, and supporting gastrointestinal function.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

VIP-5 is a synthetic analogue of vasoactive intestinal peptide (VIP), a 28–amino acid neuropeptide belonging to the secretin/glucagon peptide family. VIP plays key roles in vasodilation, smooth muscle relaxation, immune regulation, and neuroprotection. Modified versions like VIP-5 are studied for enhanced stability, bioavailability, and receptor selectivity, with research applications in pulmonary hypertension, inflammatory disorders, neurodegenerative diseases, and immune modulation.

Structure

  • Type: Synthetic VIP analogue
  • Parent Peptide: VIP (HSDAVFTDNYSRVKNAVSSELGQKQGKMNH₂, 28 aa)
  • Molecular Weight: ~3.3 kDa (native VIP; analogue-dependent)
  • Mechanism:



    Binds to VPAC1 and VPAC2 receptors (class B GPCRs)



    Increases cAMP in vascular, immune, and neuronal cells



    Produces vasodilation, anti-inflammatory effects, and neuroprotection

Research

Pulmonary & Cardiovascular Effects

  • Potent vasodilator in pulmonary vasculature.
  • Studied in pulmonary arterial hypertension (PAH) as an alternative or adjunct to prostacyclins.

Immune Modulation

  • Reduces pro-inflammatory cytokines (IL-6, TNF-α).
  • Enhances T-regulatory cell function, promoting immune tolerance.
  • Investigated in autoimmune disease and inflammatory bowel disease (IBD).

Neuroprotection

  • VIP and analogues protect neurons against ischemia, excitotoxicity, and oxidative stress.
  • Studied in Alzheimer’s, Parkinson’s, and stroke models.

Gastrointestinal Regulation

  • Modulates intestinal motility and secretion.
  • VIP deficiency implicated in IBD and IBS pathophysiology.

Safety Profile

  • Native VIP has a short half-life (~2 minutes); analogues like VIP-5 improve stability.
  • Generally well tolerated in preclinical research, with main concerns related to hypotension at higher doses.

Summary

VIP-5 is a synthetic derivative of vasoactive intestinal peptide studied for:

  • Vasodilation and pulmonary hypertension research
  • Anti-inflammatory and immune-modulatory effects
  • Neuroprotection in ischemia and neurodegeneration
  • Gastrointestinal and metabolic regulation

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term preservation, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Laburthe M, Couvineau A. Vasoactive intestinal peptide receptors: structure and function. *Biochim Biophys Acta*. 2002;1615(1-2):209–221. doi:10.1016/S0005-2736(03)00167-2

2. Said SI. Vasoactive intestinal peptide in physiology and disease. *FASEB J*. 1991;5(14):2916–2922. doi:10.1096/fasebj.5.14.1683398

3. Gozes I, et al. VIP and related peptides as neuroprotective agents. *Trends Mol Med*. 2003;9(11): 575–581. doi:10.1016/j.molmed.2003.10.001

4. Vaudry D, et al. Pituitary adenylate cyclase-activating polypeptide and VIP neuroprotection. *Trends Pharmacol Sci*. 2009;30(1):41–49. doi:10.1016/j.tips.2008.10.006

5. Prasse A, et al. Inhaled vasoactive intestinal peptide in pulmonary hypertension. *Eur Respir J*. 2003;22(2):273–277. doi:10.1183/09031936.03.00086503

6. Delgado M, et al. VIP regulates immune tolerance by inducing regulatory T cells. *Nat Immunol*. 2002;3(9):944–952. doi:10.1038/ni834

7. Harmar AJ, et al. Pharmacology of VIP and PACAP receptors. *Br J Pharmacol*. 2012;166(1):4–17. doi:10.1111/j.1476-5381.2012.01871.x

8. Said SI, et al. VIP as a cytokine: anti-inflammatory properties in lung injury. *Am J Physiol Lung Cell Mol Physiol*. 2007;293(2):L473–L480. doi:10.1152/ajplung.00045.2007

9. Dickson L, Finlayson K. VPAC and PACAP receptor pharmacology: therapeutic potential. *Pharmacol Ther*. 2009;121(3):294–316. doi:10.1016/j.pharmthera.2008.11.006

10. Abad C, et al. VIP in inflammatory and autoimmune disorders: therapeutic implications. *Mol Cell Endocrinol*. 2011;335(1):9–17. doi:10.1016/j.mce.2010.06.018